Squarepoint’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-6,557
| Closed | -$545K | – | 4352 |
|
|
2025
Q3 | $545K | Sell |
6,557
-74,941
| -92% | -$5.42M | ﹤0.01% | 3167 |
|
|
2025
Q2 | $5.98M | Sell |
81,498
-155,335
| -66% | -$11.3M | 0.01% | 1344 |
|
|
2025
Q1 | $27.1M | Buy |
+236,833
| New | +$14.4M | 0.03% | 560 |
|
|
2024
Q2 | – | Sell |
-44,007
| Closed | -$1.11M | – | 4138 |
|
|
2024
Q1 | $1.11M | Sell |
44,007
-30,504
| -41% | -$721K | ﹤0.01% | 2515 |
|
|
2023
Q4 | $2.42M | Buy |
74,511
+16,564
| +29% | +$455K | ﹤0.01% | 1876 |
|
|
2023
Q3 | $1.58M | Sell |
57,947
-22,813
| -28% | -$660K | ﹤0.01% | 2001 |
|
|
2023
Q2 | $1.8M | Buy |
+80,760
| New | +$1.86M | 0.01% | 1723 |
|
|
2023
Q1 | – | Sell |
-22,627
| Closed | -$460K | – | 3312 |
|
|
2022
Q4 | $460K | Sell |
22,627
-10,957
| -33% | -$275K | ﹤0.01% | 2329 |
|
|
2022
Q3 | $861K | Sell |
33,584
-28,261
| -46% | -$756K | ﹤0.01% | 1865 |
|
|
2022
Q2 | $1.47M | Sell |
61,845
-50,849
| -45% | -$1.11M | 0.01% | 1371 |
|
|
2022
Q1 | $2.54M | Buy |
112,694
+40,799
| +57% | +$868K | 0.01% | 1009 |
|
|
2021
Q4 | $1.42M | Buy |
71,895
+59,285
| +470% | +$1.2M | ﹤0.01% | 1472 |
|
|
2021
Q3 | $248K | Buy |
+12,610
| New | +$264K | ﹤0.01% | 2359 |
|
|
2021
Q1 | – | Sell |
-63,448
| Closed | -$1.66M | – | 3184 |
|
|
2020
Q4 | $1.66M | Buy |
+63,448
| New | +$1.34M | 0.01% | 1033 |
|
|
2020
Q3 | – | Sell |
-18,113
| Closed | -$305K | – | 2528 |
|
|
2020
Q2 | $305K | Sell |
18,113
-46,913
| -72% | -$659K | ﹤0.01% | 1591 |
|
|
2020
Q1 | $773K | Buy |
+65,026
| New | +$805K | 0.02% | 833 |
|
|
2019
Q4 | – | Sell |
-24,697
| Closed | -$349K | – | 2515 |
|
|
2019
Q3 | $349K | Sell |
24,697
-148,674
| -86% | -$1.83M | ﹤0.01% | 1817 |
|
|
2019
Q2 | $1.93M | Buy |
173,371
+29,788
| +21% | +$332K | 0.02% | 868 |
|
|
2019
Q1 | $1.69M | Buy |
143,583
+32,044
| +29% | +$398K | 0.02% | 850 |
|
|
2018
Q4 | $1.49M | Buy |
+111,539
| New | +$1.47M | 0.02% | 779 |
|
|
2018
Q3 | – | Sell |
-57,997
| Closed | -$912K | – | 2011 |
|
|
2018
Q2 | $912K | Sell |
57,997
-269,594
| -82% | -$4.69M | 0.01% | 930 |
|
|
2018
Q1 | $5.39M | Buy |
327,591
+297,864
| +1,002% | +$5.52M | 0.09% | 294 |
|
|
2017
Q4 | $537K | Buy |
29,727
+4,166
| +16% | +$75.5K | 0.01% | 1165 |
|
|
2017
Q3 | $493K | Sell |
25,561
-13,939
| -35% | -$208K | 0.01% | 985 |
|
|
2017
Q2 | $466K | Buy |
39,500
+23,984
| +155% | +$261K | 0.01% | 982 |
|
|
2017
Q1 | $170K | Sell |
15,516
-25,584
| -62% | -$225K | ﹤0.01% | 1324 |
|
|
2016
Q4 | $298K | Buy |
+41,100
| New | +$322K | 0.01% | 1154 |
|
Other funds holding CORT
ISL
PA
Squarepoint's CORT Position: Q4 2025 in Review
Squarepoint sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 6,557 shares — an estimated $545K sold.
Squarepoint first reported a position in CORT in Q4 2016 and held it in 27 quarters. The position peaked at $27.1M in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.
- Squarepoint reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
- Squarepoint sold 6,557 Corcept Therapeutics shares in Q4 2025, an estimated $545K.
- Squarepoint first reported a position in Corcept Therapeutics in Q4 2016 and held it in 27 quarters.
- Squarepoint's Corcept Therapeutics position peaked at $27.1M in Q1 2025.
- 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.
Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.